ImageneBio, Inc.

IMA Healthcare Biotechnology

ImageneBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $800,000.00, down 77.1% from fiscal 2024.

Revenue
−60.1%
EPS
+85.9%
Free cash flow
+23.8%

Quarter to June 2026, against a year earlier

4.11 0.06 −1.44%
Market cap
$47.3M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−1.12
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(38.94%) 225.87% (44.61%) (41.34%)
ROA
(34.44%) (62.04%) (40.29%) (38.34%)
ROIC
0.00% 0.00% (557.03%) (622.37%)
Return on Tangible Assets
(39.12%) (40.60%) (46.71%) (39.64%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(5.17) (9.82) (4.94) (3.25)
Free Cash Flow
(44.10) (47.84) (55.41) (52.59)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026